The campaign, sponsored by the World Health Organization as part of its polio eradication efforts, vaccinated 500,000 children, aged 4 – 59 months, over a one-week period in early 2019. Data on acceptability of the PharmaJet Tropis Needle-Free Injection System was collected from 610 vaccinators and 4,898 caregivers. Of those with prior needle and syringe…
Invectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients.
Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response.
Immunization coverage is critical to eradicating potentially deadly diseases while reducing the burden of disease. Safe, cost-effective, and patient-friendly injectable drug delivery systems play a crucial role in the success of global vaccination programs. PharmaJet leverages innovative jet injection technology to offer a needle-free, accurate, and more comfortable method of vaccine delivery. With unparalleled ease-of-use…
Needle-free Injection technology has evolved significantly over the last 50 years and is now accepted in many routine immunization settings as a safe and effective vaccine delivery method. Disposable syringe jet injectors are now being used for the delivery of vaccines to eradicate polio, MMR, and influenza, and are showing promising results in vaccine clinical…
The Lancet recently published a study that demonstrates that the delivery of a Zika virus vaccine with the PharmaJet Stratis Needle-free Jet injector resulted in a higher immune response as compared with administration via needle and syringe.
Administration of intradermal fractional dose of inactivated poliovirus vaccine (fIPV) has proven to be safe and immunogenic; however, intradermal injection using needle and syringe is technically difficult and requires trained personnel.
The polio eradication endgame strategic plan calls for the sequential removal of Sabin poliovirus serotypes from the trivalent oral poliovirus vaccine (tOPV), starting with type 2, and the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV), to maintain an immunity base against poliovirus type 2.
ONdrugDELIVERY publishes PharmaJet Study
Offering needle-free technology in a workplace influenza immunization program has the potential to help address an unmet need for increasing workplace health immunization rates.
A randomized controlled trial was conducted in Cuba to determine immune responses after one fractional dose (0.1mL or 1/5 the dose size) of inactivated poliovirus vaccine using the PharmaJet Tropis jet Injector, as compared to a full dose (0.5mL) with traditional needle and syringe intradermal technique.